ClinicalTrials.gg
Not yet recruitingNCT07114107VATUpdated Aug 11, 2025

Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion

An interventional study of VPAT (Vibratory Positive Pressure Therapeutic Apparatus) and basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA in Atopic Rhinitis and Atopic Asthma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
12 Years to 50 Years
Sex
All
01

Study summary

This is a prospective study. It enrolls subjects with allergic rhinitis, with or without asthma, who have nasal congestion as the main symptom and meet the inclusion criteria, aiming to evaluate the efficacy and safety of acoustic vibration combined with an oscillating positive expiratory pressure device in the treatment of patients with nasal congestion. On the premise that subjects agree to use basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA), they are instructed to use the acoustic vibration therapy device and the oscillating positive expiratory pressure therapy device respectively, 3 times a day for 3 minutes each time. Indicators related to nasal congestion will be measured immediately after a single use, as well as at 2 weeks, 4 weeks, and 8 weeks of use, so as to monitor the improvement of nasal ventilation and accompanying symptoms in the subjects.

Read the detailed description

Objective: To evaluate the efficacy and safety of acoustic vibration combined with an oscillating positive expiratory pressure device in the treatment of patients with nasal congestion.

Methods: A total of 200 subjects with nasal congestion as the main symptom who met the inclusion criteria were enrolled in this study. Among them, 100 subjects were treated with an acoustic vibration therapy device (treatment group), including 50 subjects with allergic rhinitis and 50 subjects with allergic rhinitis complicated with asthma; the other 100 subjects were treated with an oscillating positive expiratory pressure therapy device (without acoustic function, only with oscillating positive expiratory pressure function) as the control group, which also included 50 subjects with allergic rhinitis and 50 subjects with allergic rhinitis complicated with asthma. On the premise that subjects agreed to use basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA), they were instructed to use the acoustic vibration therapy device or the oscillating positive expiratory pressure therapy device, respectively, 3 times a day for 3 minutes each time. Nasal congestion-related indicators were measured immediately after a single use, as well as at 2 weeks, 4 weeks, and 8 weeks of use. The improvement of nasal ventilation and accompanying symptoms was monitored to clarify the efficacy and safety of the two devices.

Key Inclusion Criteria:

Subjects aged 12-50 years at the time of signing the informed consent form, regardless of gender;Meeting the guideline diagnostic criteria for allergic rhinitis with or without asthma;Presenting with significant nasal congestion for at least 1 week, with or without asthma, and symptoms poorly controlled despite the use of intranasal glucocorticoids and/or other therapeutic drugs;Patients with moderate to severe seasonal allergic rhinitis (SAR) with a mean Total Nasal Symptom Score (TNSS) ≥ 9 points, including nasal congestion ≥ 3 points;Willing and able to complete follow-up visits and scoring assessments at 2 weeks, 4 weeks, and 8 weeks during the study period as required by the protocol;Regular use of standard medications;Willing to receive treatment with acoustic vibration or oscillating positive expiratory pressure device 3 times a day for 3 minutes each time, and perform corresponding check-in and reporting;Voluntarily signing the informed consent form before the start of any study-related procedures, able to communicate smoothly with researchers, understand and be willing to strictly comply with the requirements of this clinical study protocol to complete the study.

Expected Outcomes:

Statistically significant improvements in relevant parameters in the oscillating positive expiratory pressure therapy device group after treatment, including: Peak Nasal Inspiratory Flow (PNIF), Peak Expiratory Flow (PEF), Fractional Exhaled Nitric Oxide(FeNO), Visual Analogue Scale (VAS), Total Nasal Symptom Score + Total Non-Nasal Symptom Score (TNSS + TNNSS), Rhinitis-Related Quality of Life Questionnaire (RQLQ), Asthma Control Test (ACT), Asthma Quality of Life Questionnaire (AQLQ), anterior rhinoscope (ENT), Pulmonary Function Tests, etc. The safety of acoustic vibration therapy device and oscillating positive expiratory pressure therapy device in the treatment of nasal congestion will be clarified, specifically including the incidence of adverse events such as no epistaxis, dyspnea, etc.

Hypothesis:

In the treatment of subjects with nasal congestion as the main symptom, whether they have simple allergic rhinitis or allergic rhinitis complicated with asthma, nasal congestion and related symptoms are significantly improved after daily treatment with acoustic vibration or oscillating positive expiratory pressure devices 3 times a day.

02

Conditions studied

  • Atopic Rhinitis
  • Atopic Asthma

Keywords

  • nasal congestion
  • Vibroacoustic therapy
  • Oscillating Positive Expiratory Pressure
03

In context

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

This study's planned enrollment of 200 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.

Browse Rhinitis, Allergic, Perennial studies →

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 12-50 years at the time of signing the form, regardless of gender; Meeting the guideline diagnostic criteria for allergic rhinitis with or without asthma; Presenting with significant nasal congestion for at least 1 week, with or without asthma, and symptoms poorly controlled despite the use of intranasal and/or other therapeutic drugs; Patients with moderate to severe seasonal allergic rhinitis (SAR) with a mean Total Nasal Symptom Score (TNSS) ≥ 9 points, including nasal congestion ≥ 3 points; Willing and able to complete follow-up visits and scoring assessments at 2 weeks, 4 weeks, and 8 weeks during the study period as required by the protocol; Regular use of standard medications; Willing to receive treatment with acoustic vibration or oscillating positive expiratory pressure device 3 times a day for 3 minutes each time, and perform corresponding check-in and reporting; Voluntarily signing the informed consent form before the start of any study-related procedures, able to communicate smoothly with researchers, understand and be willing to strictly comply with the requirements of this clinical study protocol to complete the study.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria identified by pre-examination with nasal endoscopy include: definite structural/mechanical obstruction (moderate-to-severe nasal septum deviation, moderate-to-severe nasal valve collapse, grade 3-4 nasal polyps, and inferior turbinate hypertrophy that may reduce decongestion reversibility); A history of severe epistaxis within 3 months, or use of anticoagulants; Complicated with unstable asthma; Patients currently receiving special treatment regimens, including biologic therapy and dust mite desensitization therapy; Complicated with major diseases of the respiratory or cardiovascular system: such as moderate-to-severe , coronary heart disease, bronchiectasis, pulmonary infection, or respiratory tract infection; Suffering from malignant tumors or having a history of malignant tumors (except for cutaneous squamous cell carcinoma, basal cell carcinoma, or cervical carcinoma in situ that have been completely resected with no evidence of recurrence); Having undergone major surgery within 3 months before randomization, or planning to undergo major surgery during the study period; Suffering from severe concomitant diseases or other conditions that, in the investigator's judgment, make the patient unsuitable for participation in this trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    treatment group 1-nasal congestion with only atopic rhinitis

    this group participants use the acoustic vibration device therapy device, respectively, 3 times a day for 3 minutes each time for 2 month

    Device: VPAT (Vibratory Positive Pressure Therapeutic Apparatus) · Drug: basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA

  • Experimental
    treatment group 2-nasal congestion with atopic rhinitis and atopic asthma

    this group participants use the acoustic vibration device therapy device, respectively, 3 times a day for 3 minutes each time for 2 month

    Device: VPAT (Vibratory Positive Pressure Therapeutic Apparatus) · Drug: basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA

  • Active comparator
    control group 1-nasal congestion with only atopic rhinitis

    this group participants use the oscillating positive expiratory pressure therapy device (without acoustic function), respectively, 3 times a day for 3 minutes each time for 2 months.

    Drug: basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA · Device: OPEP(Oscillating Positive Expiratory Pressure device)

  • Active comparator
    control group 2-nasal congestion with atopic rhinitis and atopic ashtma

    this group participants use the oscillating positive expiratory pressure therapy device (without acoustic function), respectively, 3 times a day for 3 minutes each time for 2 months.

    Drug: basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA · Device: OPEP(Oscillating Positive Expiratory Pressure device)

Interventions

  • DeviceVPAT (Vibratory Positive Pressure Therapeutic Apparatus)

    VPAT (Vibratory Positive Pressure Therapeutic Apparatus)is a physical solution which can relieve nasal congestion and discomforts by applying acoustic vibration and oscillatory positive expiratory pressure. Clinical research has shown that low-frequency vibration at approximately 130 Hz promotes the production of the highest concentration of Nitric Oxide (NO) in the paranal sinuses, which helps to regulate the nasal mucosal blood, restoring the mucous membrance-cilia mechanism, clean up the bacteria, viruses and allergenic particles in the respiratory tract. Combined with Oscillatory Positive Expiratory Pressure and Transnasal Breathing, it can help to cultivate the habit of nasal breathing and slow breathing, as well as to restore the function of lungs.

  • Drugbasic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA

    All participants need basic control drugs contains antihistamines(Ebastine 10 mg once daily for 2 weeks), mometasone furoate nasal spray(Spray 2 puffs into each nostril, each puff contains 50 μg of mometasone furoate, i.e., 100 μg per administration, once daily for 2 weeks). Asthma participants should added Inhaled corticosteroids-long-acting beta-agonists (ICS-LABA) therapy. For mild to moderate asthma: budesonide/formoterol (160μg/4.5μg) , with 1 inhalation each time, twice daily, or salmeterol/fluticasone propionate (50μg/100μg) with 1 inhalation each time, twice daily. For moderate to severe asthma: Budesonide/Formoterol (320μg/4.5μg), with 1 inhalation each time, twice daily; or salmeterol/fluticasone propionate (50μg/250μg or 50μg/500μg) with 1 inhalation each time, twice daily. Dosage adjustments should be evaluated and determined by the physician based on the patient's disease control status.

  • DeviceOPEP(Oscillating Positive Expiratory Pressure device)

    Oscillating Positive Expiratory Pressure (OPEP) device contain a inner ball that creates a resistance and oscillates when the patient blows through the device. This resistance helps splint the airways open during exhalation whilst the oscillation loosens the mucous within the airways. This makes it easier for some patients to clear their sputum.

06

What researchers measure

Primary outcomes

  1. Peak Nasal Inspiratory Flow (PNIF)

    PNIF is a simple, portable inspiratory flow meter, which measures PNIF (peak nasal inspiratory flow) through the nasal passage; providing information of nasal obstruction. Objective measurement of nasal obstruction is useful in the diagnosis of a number of conditions and establishing efficacy of nasal decongestants, it can be Individually calibrated and used during assessment of allergic rhinitis.

    Time frame: These indicators are measured at baseline, immediately after a single use, and at 2 weeks, 4 weeks, and 8 weeks of use.

Secondary outcomes

  1. Peak Expiratory Flow (PEF)

    Time frame: These indicators are measured at baseline, immediately after a single use, and at 2 weeks, 4 weeks, and 8 weeks of use.

  2. VAS (Visual Analogue Scale )

    Time frame: These indicators are measured at baseline, immediately after a single use, and at 2 weeks, 4 weeks, and 8 weeks of use.

  3. Total Nasal Symptom Score + Total Non-Nasal Symptom Score (TNSS + TNNSS)

    Time frame: These indicators are measured at baseline, 2 weeks, 4 weeks, and 8 weeks of use.

  4. RQLQ(Rhinitis-Related Quality of Life Questionnaire )

    Time frame: These indicators are measured at baseline, 2 weeks, 4 weeks, and 8 weeks of use.

  5. FeNO (Fractional Exhaled Nitric Oxide)

    Time frame: These indicators are measured at baseline, immediately after a single use, and at 2 weeks, 4 weeks, and 8 weeks of use.

  6. ACT(Asthma Control Test )

    Time frame: These indicators are measured at baseline, 2 weeks, 4 weeks, and 8 weeks of use.

  7. AQLQ(Asthma Quality of Life Questionnaire )

    Time frame: These indicators are measured at baseline, 2 weeks, 4 weeks, and 8 weeks of use.

  8. anterior rhinoscope

    The anterior rhinoscope is used to examine for the presence of bleeding, aggravated ulcers, and other conditions, so as to ensure that adverse reactions such as increased bleeding and severe hemorrhage (which may result from the potential aggravation of ulceration and erosion in areas like the nasal vestibule) do not occur during the treatment process.

    Time frame: These indicators are measured at baseline, 2 weeks, 4 weeks, and 8 weeks of use.The anterior rhinoscope is used to examine for the presence of bleeding, aggravated ulcers.

  9. Pulmonary Function Test FEV1/FVC ratio

    We will examine the patients' pulmonary function test data at the time of enrollment and after 8 weeks of treatment, respectively. Specifically, this will mainly include improvements in the statistical results of FEV1/FVC%Pred (predicted percentage of forced expiratory volume in 1 second to forced vital capacity ratio)

    Time frame: up to 8 weeks

  10. Pulmonary Function Test

    We will examine the patients' pulmonary function test FEV1%Pred (predicted percentage of forced expiratory volume in 1 second).

    Time frame: up to 8 weeks

07

Study locations

1 site
  • Huiying Wang
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Mar 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Aug 11, 2025
StartEst.
Aug 2025
Primary completionEst.
Mar 2026
CompletionEst.
May 2026
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07114107
Collaborators
Huzhou Central Hospital, The Children's Hospital of Zhejiang University School of Medicine, First People's Hospital of Hangzhou
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Aug 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Aug 11, 2025

Study contacts

Huiying Wang, Doctor(PhD,MD)
Contact
marywang@zju.edu.cn
86(0571)-87783627
Huiying Wang
study director · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion